Payment overview · 2025
General Payments
$114.75
6 reported records · 6 companies
Healthcare provider profile · identity verified
William Mickey Wike, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NEW BERN, NC · NPI 1235187535
Verified facts
What the public records show
CMS Open Payments records show William Mickey Wike, M.D. received $114.75 in general payments during 2025 across 6 reported records.
Boston Scientific Corporation accounted for 22.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $25.43 | 22.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.15 | 21.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.87 | 19.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.15 | 13.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.68 | 12.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.47 | 11.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $114.75 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Intracept Normalized: intracept |
Device | Boston Scientific Corporation | $25.43 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $24.15 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.68 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
33 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
88 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 524 | 126 |
| Atorvastatin Calcium | Atorvastatin Calcium | 500 | 126 |
| Levothyroxine Sodium | Levothyroxine Sodium | 403 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 373 | 85 |
| Omeprazole | Omeprazole | 319 | 78 |
| Losartan Potassium | Losartan Potassium | 309 | 74 |
| Gabapentin | Gabapentin | 288 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 275 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 258 | 65 |
| Lisinopril | Lisinopril | 247 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 243 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 240 | 58 |
| Metformin Hcl | Metformin Hcl | 239 | 55 |
| Tramadol Hcl | Tramadol Hcl | 206 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 205 | 52 |
| Potassium Chloride | Potassium Chloride | 182 | 51 |
| Meloxicam | Meloxicam | 171 | 47 |
| Jardiance | Empagliflozin | 170 | 23 |
| Alendronate Sodium | Alendronate Sodium | 151 | 37 |
| Glipizide Er | Glipizide | 150 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 147 | 33 |
| Furosemide | Furosemide | 146 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 139 | 44 |
| Pioglitazone Hcl | Pioglitazone Hcl | 135 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 121 | 28 |
| Allopurinol | Allopurinol | 119 | 26 |
| Eliquis | Apixaban | 118 | 19 |
| Ezetimibe | Ezetimibe | 118 | 27 |
| Spironolactone | Spironolactone | 115 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 113 | 17 |
| Valsartan | Valsartan | 110 | 32 |
| Montelukast Sodium | Montelukast Sodium | 108 | 26 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 105 | 26 |
| Metformin Hcl Er | Metformin Hcl | 103 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 103 | 31 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 100 | 20 |
| Simvastatin | Simvastatin | 93 | 24 |
| Trazodone Hcl | Trazodone Hcl | 90 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 89 | 24 |
| Ozempic | Semaglutide | 88 | 17 |
| Glimepiride | Glimepiride | 82 | 14 |
| Carvedilol | Carvedilol | 80 | 16 |
| Methylprednisolone | Methylprednisolone | 80 | 70 |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | 13 |
| Famotidine | Famotidine | 75 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 19 |
| Lorazepam | Lorazepam | 73 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 17 |
| Farxiga | Dapagliflozin Propanediol | 65 | 16 |
| Telmisartan | Telmisartan | 65 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 64 | 13 |
| Glipizide | Glipizide | 63 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 11 |
| Synthroid | Levothyroxine Sodium | 53 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 51 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 14 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 50 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 50 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | 12 |
| Ibuprofen | Ibuprofen | 46 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 43 | suppressed |
| Januvia | Sitagliptin Phosphate | 43 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 30 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 40 | 13 |
| Donepezil Hcl | Donepezil Hcl | 40 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | suppressed |
| Finasteride | Finasteride | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Prednisone | Prednisone | 36 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 35 | 15 |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Alprazolam | Alprazolam | 34 | suppressed |
| Febuxostat | Febuxostat | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Celecoxib | Celecoxib | 33 | 11 |
| Diazepam | Diazepam | 33 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 33 | 28 |
| Atenolol | Atenolol | 32 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 32 | suppressed |
| Linzess | Linaclotide | 32 | suppressed |
| Novolog Flexpen | Insulin Aspart | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 14 |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 29 |
| Meclizine Hcl | Meclizine Hcl | 29 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 29 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 14 |
| Indapamide | Indapamide | 28 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 28 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 28 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 11 |
| Bupropion Hcl | Bupropion Hcl | 22 | suppressed |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Klor-Con M20 | Potassium Chloride | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Jantoven | Warfarin Sodium | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Nexium | Esomeprazole Magnesium | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Sulindac | Sulindac | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Etodolac | Etodolac | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $114.75 · 6 records | Boston Scientific Corporation | Dexcom G6 Transmitter, Intracept, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error